Novo Nordisk (NOVOB DC) announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus, building on continued efforts to expand access
Importance
Level 1
- New, lower list price of USD 675/month across Wegovy, Ozempic, and Rybelsus, effective January 1st, 2027.
- These changes in list price do not have an impact on direct-to-patient, self-pay prices
- Decision applies to all doses of these medicines.
#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US SESSION#GLOBAL EQUITIES